Morgan Stanley (NY:MS)

191.17 +0.98 (+0.52%)

Delayed Quote Updated: 3:18 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Morgan Stanley

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Alnylam Highlights AMVUTTRA Momentum, Resets 2026 TTR Revenue Outlook ↗

September 20, 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) highlighted continued momentum for its AMVUTTRA treatment in transthyretin-mediated cardiomyopathy, while outlining a pipeline of upcoming clinical catalysts and...

Via MarketBeat

IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth Targets ↗

September 20, 2026

IDEXX Laboratories (NASDAQ:IDXX) executives highlighted the company’s diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare...

Via MarketBeat

Topics ETFs

IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley Conference ↗

September 20, 2026

IDEXX Laboratories (NASDAQ:IDXX) executives reiterated the company’s long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product...

Via MarketBeat

Topics ETFs

Sanofi Eyes €25B Dupixent Future, Expands M&A Hunt Ahead of Patent Loss ↗

September 20, 2026

Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the...

Via MarketBeat

Topics Intellectual Property

Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push ↗

September 20, 2026

Pacific Biosciences of California (NASDAQ:PACB) is maintaining its existing strategy while sharpening execution around clinical genomics, cost controls and the rollout of products designed to improve...

Via MarketBeat

Rockwell Automation Sees Data Centers, Labor Crunch Fueling Automation Demand ↗

September 19, 2026

Rockwell Automation (NYSE:ROK) executives said customer sentiment remains broadly positive despite inflation, tariffs and trade-policy uncertainty, with manufacturers continuing to prioritize...

Via MarketBeat

Topics Economy World Trade

Cardinal Health Targets 13%-15% EPS Growth as Specialty Momentum Builds ↗

September 19, 2026

Cardinal Health (NYSE:CAH) CEO Jason Hollar said the company expects fiscal 2027 to extend the broad operating momentum it generated in fiscal 2026, with all five operating segments positioned for what...

Via MarketBeat

Topics World Trade

Boeing Isn't Perfect -- but It's Still a Compelling Value Buy Right Now ↗

September 19, 2026

Boeing's slow progress is not being recognized yet by the market.

Via The Motley Fool

Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction ↗

September 19, 2026

Axsome Therapeutics (NASDAQ:AXSM) executives said the company is seeing accelerating prescription growth for AUVELITY following its sales-force expansion and the recent launch of the drug in...

Via MarketBeat

26 Analysts Covering SpaceX Stock Rate It a Buy. Here's Why 8 Analysts Disagree ↗

September 19, 2026

Wall Street remains very bullish on SpaceX stock.

Via The Motley Fool

Topics Artificial Intelligence Initial Public Offering

United Rentals Sees Large-Project Pipeline Accelerate as Specialty Demand Stays Strong ↗

September 19, 2026

United Rentals (NYSE:URI) executives said construction-equipment rental demand has exceeded the company’s expectations this year, led by an accelerating pipeline of large projects and supported by...

Via MarketBeat

Topics Bonds Economy Energy

Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks ↗

September 19, 2026

Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while...

Via MarketBeat

Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances ↗

September 19, 2026

Intellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company’s ongoing Phase III program in...

Via MarketBeat

Topics Intellectual Property

BioCryst Eyes $1B Rare-Disease Future Through External Innovation ↗

September 18, 2026

BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief...

Via MarketBeat

Arrowhead Pharmaceuticals Spotlights Dual-Target RNAi Data, Plozasiran Launch Progress ↗

September 18, 2026

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined early clinical data for its RNA interference dimer program, progress in the launch of plozasiran and plans for central nervous system and...

Via MarketBeat

L3Harris Pivots to Execution as New CEO Targets Radio, Space Growth ↗

September 18, 2026

L3Harris Technologies (NYSE:LHX) is entering its leadership transition with an emphasis on operating execution rather than further portfolio reshaping, according to Chief Financial Officer Ken Sharp....

Via MarketBeat

SpaceX Stock Is Down 33% From Its High. Here's Why Morgan Stanley Thinks There's 106% Upside From Here. ↗

September 18, 2026

SpaceX's valuation now hovers just below $2 trillion.

Via The Motley Fool

Topics Economy Initial Public Offering

SpaceX Stock Is Down 28% From Its All-Time High. Here's What $10,000 Invested Today Could Be Worth by 2031. ↗

September 18, 2026

After a blockbuster 2026 debut, where will SpaceX be in 2031?

Via The Motley Fool

Topics Initial Public Offering

BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone ↗

September 18, 2026

BioMarin Pharmaceutical (NASDAQ:BMRN) said it is progressing with the integration of Amicus Therapeutics while pursuing additional business-development opportunities, as executives outlined growth...

Via MarketBeat

Accenture (ACN) Stock Trades Down, Here Is Why

September 18, 2026

What Happened? Shares of global professional services company Accenture (NYSE:ACN) fell 3.3% in the afternoon session after Guggenheim analyst Jonathan Lee d...

Via StockStory

J.B. Hunt's Stock Plunges After Market Misprices Profit Warning ↗

September 18, 2026

J.B. Hunt warned of higher driver-related costs, sending shares down, but analysts trimmed price targets while raising others, keeping a Moderate Buy rating amid sector-wide trucking pressure.

Via MarketBeat

NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even ↗

September 18, 2026

NovoCure (NASDAQ:NVCR) outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan...

Via MarketBeat

The HBM Bottleneck: 3 Tech Companies Have Locked Up 85% of the Supply of AI's Scarcest Asset ↗

September 18, 2026

Nvidia, Alphabet, and AMD have already bought most of the high bandwidth memory that will be manufactured next year.

Via The Motley Fool

Topics Artificial Intelligence

Fed Chair Kevin Warsh Raises Interest Rates for the First Time in Over 3 Years. These AI Stocks Will Benefit ↗

September 18, 2026

AI investors should choose carefully as interest rates rise.

Via The Motley Fool

Topics Artificial Intelligence Economy

GE Vernova Eyes $200B Backlog Early in 2027 as Power Demand Surges ↗

September 18, 2026

GE Vernova (NYSE:GEV) expects to reach its previously stated $200 billion backlog target early in 2027, supported by continued demand for power-generation and electrification equipment, Chief Executive...

Via MarketBeat

Topics Artificial Intelligence Earnings

Anthropic Is Expected to Go Public in October. The Brokerages Get Paid Either Way. ↗

September 18, 2026

The two lead advisors generated record revenue in Q2, fueled by the SpaceX IPO. Will the Anthropic IPO have a similar impact?

Via The Motley Fool

Topics Artificial Intelligence Initial Public Offering

Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales ↗

September 18, 2026

Zoetis (NYSE:ZTS) executives said the company remains confident in its previously issued guidance despite pressure in the U.S. companion-animal market, citing a weaker pet-care environment and...

Via MarketBeat

2 Russell 2000 Stocks with Competitive Advantages and 1 That Underwhelm

September 18, 2026

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...

Via StockStory

Norfolk Southern Sees Fuel Hit but Eyes Freight Share Gains From Trucking ↗

September 17, 2026

Norfolk Southern (NYSE:NSC) said higher fuel prices are expected to pressure its operating ratio in the second half of the year, reversing the tailwind management had anticipated just two months...

Via MarketBeat

Topics Energy

This eVTOL Stock Could Turn $1,000 Into $100,000 ↗

September 17, 2026

Joby Aviation is flying high over a multitrillion-dollar opportunity.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.